Mereo BioPharma Group plc 8-K

What Happened

• Mereo BioPharma Group plc (MREO) filed an 8-K reporting results of its Annual General Meeting held May 14, 2026. A total of 436,766,255 ordinary shares were represented in person or by proxy. All resolutions put to the meeting were passed as proposed.
• Key outcomes: PricewaterhouseCoopers LLP (PwC) was re‑appointed as auditor; the directors’ remuneration report and remuneration policy were approved (the latter to take effect from the end of the AGM); an advisory (non‑binding) vote on named executive officer compensation was approved; Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz were re‑elected; and directors were granted authority to allot shares and to allot shares for cash on a non‑pre‑emptive basis up to a maximum nominal amount of £3,591,354.73 (authority expires June 30, 2029).

Key Details

• Shares represented: 436,766,255 ordinary shares present or by proxy at the AGM.
• Auditor reappointment: PwC re‑appointed with 429,804,470 votes for (98.59% of shares voted), 6,156,620 against.
• Remuneration approvals: directors’ remuneration report approved (295,564,225 for, 6.65% against); remuneration policy approved (290,456,675 for, 8.26% against); advisory pay vote approved (290,149,130 for, 8.29% against). Note: ~120 million "votes withheld" on several resolutions (not counted as votes under law).
• Share authority: Directors authorized to allot shares and grant rights up to £3,591,354.73 and to allot for cash on a non‑pre‑emptive basis; share allotment resolutions passed with ~80.5% of votes cast in favor (254,7xx,730 for vs 61,5xx,760 against).

Why It Matters

• Governance: Reappointment of PwC and the re‑election of directors maintain continuity in audit and board leadership. Approval of the directors’ remuneration report and policy formalizes executive pay rules going forward.
• Capital flexibility: The new allotment and non‑pre‑emptive authorities (to June 30, 2029) give the board flexibility to issue shares or raise capital without offering pre‑emptive rights first — a potential source of dilution if used.
• Investor signal: While most resolutions passed with strong support, the sizeable number of votes withheld/against on pay and allotment matters is a governance signal investors may monitor for shareholder concern on compensation and dilution.